Lamm DL - Search Results

1

Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.

Sylvester RJ, van der MEIJDEN AP, Lamm DL. Sylvester RJ, et al. Among authors: lamm dl. J Urol. 2002 Nov;168(5):1964-70. doi: 10.1016/S0022-5347(05)64273-5. J Urol. 2002. PMID: 12394686

2

International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer.

Roumiguié M, Kamat AM, Bivalacqua TJ, Lerner SP, Kassouf W, Böhle A, Brausi M, Buckley R, Persad R, Colombel M, Lamm D, Palou-Redorta J, Soloway M, Brothers K, Steinberg G, Lotan Y, Sylvester R, Alfred Witjes J, Black PC. Roumiguié M, et al. Eur Urol. 2022 Jul;82(1):34-46. doi: 10.1016/j.eururo.2021.12.005. Epub 2021 Dec 23. Eur Urol. 2022. PMID: 34955291 Review.

3

Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group.

Kamat AM, Sylvester RJ, Böhle A, Palou J, Lamm DL, Brausi M, Soloway M, Persad R, Buckley R, Colombel M, Witjes JA. Kamat AM, et al. Among authors: lamm dl. J Clin Oncol. 2016 Jun 1;34(16):1935-44. doi: 10.1200/JCO.2015.64.4070. Epub 2016 Jan 25. J Clin Oncol. 2016. PMID: 26811532 Free PMC article. Review.

4

Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses?

Lamm DL, van der Meijden AP, Akaza H, Brendler C, Hedlund PO, Mizutani Y, Ratliff TL, Robinson MR, Shinka T. Lamm DL, et al. Int J Urol. 1995 Jun;2 Suppl 2:23-35. Int J Urol. 1995. PMID: 7553302 Free article. Review. No abstract available.

5

A practical guide to the use of intravesical BCG for the management of stage Ta, T1, CIS, transitional cell cancer.

Brosman SA, Lamm DL, van der Meijden AP, Debruyne FM. Brosman SA, et al. Among authors: lamm dl. Prog Clin Biol Res. 1989;310:311-23. Prog Clin Biol Res. 1989. PMID: 2672019 Review.

6

Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials.

De Jager R, Guinan P, Lamm D, Khanna O, Brosman S, De Kernion J, Williams R, Richardson C, Muenz L, Reitsma D, et al. De Jager R, et al. Urology. 1991 Dec;38(6):507-13. doi: 10.1016/0090-4295(91)80166-5. Urology. 1991. PMID: 1836081

7

Antitumor activity of common antibiotics against superficial bladder cancer.

Kamat AM, Lamm DL. Kamat AM, et al. Among authors: lamm dl. Urology. 2004 Mar;63(3):457-60. doi: 10.1016/j.urology.2003.10.038. Urology. 2004. PMID: 15028437

8

Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A, Debruyne FM. Lamm DL, et al. J Urol. 1992 Mar;147(3):596-600. doi: 10.1016/s0022-5347(17)37316-0. J Urol. 1992. PMID: 1538436

9

Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.

Lamm DL, DeHaven JI, Shriver J, Sarosdy MF. Lamm DL, et al. J Urol. 1991 Apr;145(4):738-40. doi: 10.1016/s0022-5347(17)38439-2. J Urol. 1991. PMID: 2005691 Clinical Trial.

10

A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer.

Lamm DL, DeHaven JI, Shriver J, Crispen R, Grau D, Sarosdy MF. Lamm DL, et al. J Urol. 1990 Jul;144(1):65-7. doi: 10.1016/s0022-5347(17)39367-9. J Urol. 1990. PMID: 2193172 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

236 results

Search Page